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We discuss the upstream regulators of myogenesis that lead to the activation of myogenic determination
genes and subsequent differentiation, focusing on the mouse model. Key upstream genes, such as Pax3
and Pax7, Six1 and Six4, or Pitx2, participate in gene regulatory networks at different sites of skeletal muscle
formation. MicroRNAs also intervene, with emerging evidence for the role of other noncoding RNAs.
Myogenic determination and subsequent differentiation depend onmembers of theMyoD family. We discuss
new insights into mechanisms underlying the transcriptional activity of these factors.Introduction
The MyoD family of myogenic regulatory factors (MRFs) controls
the formation of skeletal muscle. More than 25 years ago it was
shown that the members of this family of basic-helix-loop-helix
(bHLH) transcription factors, when overexpressed in nonmuscle
cells, will activate the myogenic program, with suppression of
other cell fates and formation of differentiated muscle (seeWein-
traub et al., 1991). Since then the possibility of converting one
cell type to another by transdifferentiation has become a major
issue in the stem cell field. However, the phenomenon of
myogenic conversion remains remarkable in that a single tran-
scription factor can exert this overriding effect. We will discuss
the regulatory mechanisms that underlie myogenic factor func-
tion. We will also discuss the upstream factors that direct a cell
toward the skeletal muscle program, leading to activation of a
gene of the MyoD family and subsequent formation of skeletal
muscle. The focus will be on myogenesis in mammals, where
skeletal muscle cell lines and the mouse model for genetic
manipulation have facilitated molecular analyses.
The Formation of Skeletal Muscle
There are four MyoD family members. Compound mutations in
the mouse have shown that MyoD, Myf5, and Mrf4 function as
myogenic determination factors; in the absence of all three, no
skeletal muscle forms. The fourth member, Myogenin, acts as
a differentiation factor, as can Mrf4 and MyoD, controlling the
differentiation of myoblasts into skeletal muscle fibers (see Mon-
caut et al., 2013). This correlates with initial observations on the
greater efficiency of myogenic conversion by the three determi-
nation factors compared toMyogenin, as a result of the presence
of a C-terminal domain that recruits chromatin remodelling com-
plexes (see Fong and Tapscott, 2013).
Activation of myogenic determination genes in the embryo
shows distinct temporal and spatial characteristics (see Buck-
ingham and Mayeuf, 2012). Skeletal muscle in the trunk and
limbs derives from somites that progressively form by segmenta-
tion of paraxial mesoderm on either side of the neural tube,
following an anterior-posterior developmental gradient (Figure 1).The somite is initially an epithelial ball of cells that subsequently
distribute into a ventral mesenchymal sclerotome, giving rise to
the bones of the vertebral column and ribs and an adjacent
syndetome, a source of muscle tendons in the trunk. The dorsal
part of the somite, the dermomyotome, retains an epithelial
structure for longer and gives rise to dorsal dermis and all the
skeletal muscles of the trunk and limbs, as well as endothelial
and smooth muscle cells of blood vessels, and brown fat.
Myogenesis is initiated in the somite, where Myf5 is the first
myogenic regulatory gene to be activated in the epaxial domain,
adjacent to the neural tube. Subsequently this gene is activated
in the opposing hypaxial domain. The closely linkedMrf4 gene is
also activated early, although at later stages it is expressed only
in differentiating muscle cells. MyoD is transcribed after the
onset of Myf5 expression in the hypaxial and then in the epaxial
dermomyotome. Myogenic cells delaminate from the dermo-
myotome to form the underlying differentiated muscle of the
myotome, which subsequently grows and splits to form the
muscles of the trunk. Cells also delaminate from the hypaxial
dermomyotome to migrate to more distant locations, notably
to the limbs where Myf5 and MyoD are activated, leading to
skeletal muscle formation. Subsequently the central dermomy-
tome loses its epithelial structure and myogenic progenitor cells
enter the underlying myotome. These cells either activate Myf5
and MyoD and differentiate or proliferate, providing a reserve
cell population for muscle growth during development. Mainte-
nance of such a progenitor population is a common feature of
all muscle masses.
Skeletal myogenesis in the head also depends on the activa-
tion of myogenic determination genes (see Sambasivan et al.,
2011). In this case, skeletal muscles form from cranial meso-
derm, or from prechordal mesoderm in the case of the most
anterior extraocular muscles. Most head muscles derive from
the mesodermal core of the branchial arches, transitory struc-
tures that protrude ventrally in pairs from the pharynx, such
that the muscles of mastication and facial expression derive
from the first and second arches, respectively. This mesoderm
also contributes to the formation of the arterial pole of the heartDevelopmental Cell 28, February 10, 2014 ª2014 Elsevier Inc. 225
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Figure 1. Schematic Representation of Somites, First and Second Branchial Arches, and Prechordal Mesoderm that Are the Sources of
Skeletal Muscles, Shown for the Mouse Embryo
Somites mature following an anterior (A) to posterior (P) developmental gradient. NT, neural tube; NC, notochord.
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differentiation is quite different, these progenitor cells express
common upstream factors and belong to the same cell lineages.
Activation of myogenesis in the head, compared to the body,
therefore depends on different upstream factors and also
responds differently to signaling pathways. It shows site-depen-
dent regulation. Branchial-arch-derived muscles depend on
Myf5/Mrf4/MyoD, whereas extraocular muscle formation is initi-
ated by Myf5/Mrf4 and in their absence cannot be rescued by
MyoD.
Myogenesis during muscle regeneration in the adult depends
on satellite cells that are closely associated with muscle fibers.
These cells probably arise from somite-derived myogenic
progenitors in the body or from embryonic progenitors of head
muscles.When quiescent satellite cells are activated in response
to muscle damage, they proliferate and differentiate to form
newmuscle fibers. As in the embryo, their entry into myogenesis
depends on Myf5 and MyoD (Figure 2A; see Montarras et al.,
2013).
Upstream Regulators of Myogenesis
The myogenic determination factors control entry into the
myogenic program, which leads to the formation of skeletal
muscle. However, upstream of this obligatory step, other
transcription factors direct cells toward myogenesis. Their
respective roles have become clearer in the last decade, so
that a regulatory network begins to emerge.
Pax3 and Pax7
The Pax family of paired domain transcription factors play key
roles during tissue specification and organ development. In the
context of myogenesis, Pax3 and Pax7 are important upstream226 Developmental Cell 28, February 10, 2014 ª2014 Elsevier Inc.regulators (see Buckingham and Relaix, 2007). Unlike the MRFs,
Pax3 and Pax7 are not tissue specific, being also expressed in
neurectoderm, in subdomains of the brain, in the dorsal neural
tube, and in neural crest.
Pax3 Function at the Onset ofMyogenesis in the Embryo
Pax3 is expressed in presomitic mesoderm and throughout the
epithelial somite, before becoming restricted to the dermo-
myotome. It marks migrating myogenic progenitor cells that
have not yet activated the myogenic determination genes and
indeed the most striking feature of the Pax3 mutant is the lack
of limb muscles (see section on limb muscle progenitors). A
second major feature of the Pax3 mutant is cell death that is
particularly pronounced at later stages in the hypaxial domain
of the somite.
Apart from the c-met gene (Epstein et al., 1996), until recently
very few Pax3 targets had been identified in an in vivo myogenic
context. Most information was provided by analyses of cell lines
derived from alveolar rhabdomyosarcomas, muscle tumors that
are caused by a chromosomal translocation that results in a
PAX3-FKHR(FOXO1A) or PAX7-FKHR fusion protein, acting as
a strong transcriptional activator (see Robson et al., 2006). Cell
death complicates loss-of-function screens in the mouse
embryo, but a gain-of-function screen of Pax3-expressing cells
(Lagha et al., 2010) revealed genes that are up- or down-
regulated in somites and forelimbs in the presence of an allele
of Pax3 encoding a PAX3-FKHR fusion protein. These include
transcription factors and components of signaling pathways
known to affect myogenesis, including genes that are involved
at different stages in the myogenic progression of a somitic
cell (Figure 2B). In the multipotent cells of the somite, reciprocal
negative regulation between Pax3 and Foxc2 is observed.
Foxc2, like Pax3, is expressed throughout the epithelial somite.
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Figure 2. Progression of Muscle Progenitor
Cells Toward Formation of Differentiated
Skeletal Muscle
(A) The progression of adult muscle satellite cells
toward newmuscle fiber formation. Myf5 is shown
in red in the quiescent state to indicate that tran-
scripts are present but not the protein.
(B) The progression of somitic cells toward
myogenesis, showing how Pax3 activates target
genes that regulate different stages of this pro-
cess. Pax3 target genes are shown in red.
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important for bone and cartilage formation. In the dermo-
myotome, expression is reduced except in the hypaxial domain.
When the balance between Pax3 and Foxc2 expression is
manipulated in Pax3-expressing cells, the myogenic cell fate
is promoted by a relative increase in Pax3, whereas nonmyo-
genic fates of dermomyotomal cells, e.g., vascular smooth
muscle or endothelial, are promoted by higher levels of Foxc2
(Lagha et al., 2009). In the chick dermomyotome, single cell
labeling experiments have identified signaling pathways that
influence the fate of cells derived from a single progenitor,
such that BMP or Notch signaling, for example, promote
vascular versus myogenic cell fates (Ben-Yair and Kalcheim,
2008). In the mouse embryo, clonal analysis also indicates
multipotent Pax3-positive progenitors (Esner et al., 2006) for
these fates. Once Pax3-positive myogenic cells have left the
dermomyotome and entered the formingmusclemass (Figure 1),
a critical cellular equilibrium has to be maintained between self-
renewal of the progenitor cell pool and myogenesis. This
basic stem cell requirement for tissue growth depends on the
control exerted by signaling pathways (see Buckingham and
Mayeuf, 2012). Notch signaling, for example, promotes self-
renewal so that when the Notch pathway is mutated the
myogenic progenitor pool is depleted by excessive differentia-
tion, leading to a later reduction in muscle mass. FGF signaling
is also implicated in maintaining this balance. Pax3 intervenesDevelopmental Cell 28,at this level by directly controlling a
myogenic enhancer element 30 of the
Fgfr4 gene and also by affecting expres-
sion of Sprouty genes that encode
intracellular inhibitors of tyrosine kinase
receptor signaling.
At the point of entry into the myogenic
program, Pax3 regulates enhancer
elements of Myf5. The transcription of
Myf5 at different sites in the embryo is
controlled by a large number of en-
hancers distributed over more than
100 kb upstream of the gene (see Mon-
caut et al., 2013), permitting precise
spatio-temporal regulation of the onset
of myogenesis. The multitude of Myf5
enhancers that regulate expression in
the somites and the arches are exqui-
sitely specific for their target gene: they
do not activate the closely linked Mrf4
gene. This is achieved by a novel mech-anism that depends on transcription balancing sequences
(TRABSs), one of which is located in the interval defined as
the proximal arch enhancer. TRABSs act to regulate the equi-
libria between the enhancers and the promoters of Myf5 and
Mrf4 (Carvajal et al., 2008). Early activation in the epaxial der-
momyotome depends on canonical Wnt signaling from the neu-
ral tube and is modulated by Sonic Hedgehog signaling from
the midline, targeting the early epaxial enhancer (EEE) through
Tcf and Gli binding sites. Pax3 does not directly target the
EEE although it can indirectly affect it through the Dmrt1 tran-
scription factor, because Dmrt1 is a direct Pax3 target (see
Buckingham and Mayeuf, 2012). Two enhancer elements that
regulate Myf5 expression in the hypaxial somite/myotome
(at 110 kb) and in the limbs (at 57.5 kb) have been shown
to be direct Pax3 targets and their activity is Pax3 dependent.
Activity of these enhancers is also directly regulated by
signaling pathways, such that the 110 enhancer depends on
a Tead binding site, a read-out of the Hippo pathway, and
the 57.5 enhancer on essential Gli binding sites that respond
to Sonic Hedgehog signaling from the ZPA in the ventral domain
of the limb, showing how signals as well as upstream myogenic
regulators control the onset of myogenesis. The examples of
Pax3 targets cited here illustrate how this key factor orches-
trates different steps in the progression of a multipotent somitic
cell to a tissue-specific myoblast at the onset of myogenesis
(Figure 2B).February 10, 2014 ª2014 Elsevier Inc. 227
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depends genetically on Myf5 and also on Pax3 because
in Myf5(Mrf4)/Pax3 compound mutants, no skeletal muscle
forms in the trunk and limbs (Tajbakhsh et al., 1997). Embryonic
expression of MyoD depends on an enhancer at 20 kb
(CE) from the gene (see Tapscott, 2005), which is not a
direct Pax3 target, although a Pax binding site in the MyoD
promoter is targeted by Pax7 in postnatal muscle cells (Hu
et al., 2008).
The Role of Pax7 during Fetal and Postnatal Myogenesis
Whereas Pax3 is expressed in all myogenic progenitor cells in the
embryo, Pax7 is mainly present in the central domain of the der-
momyotome and in the absence of Pax3 it is this domain that sur-
vives. These Pax3/Pax7-positive cells provide the self-renewing
reserve cell population for muscle growth (see Buckingham,
2006). In double Pax3/Pax7 mutants, these cells fail to activate
Myf5 orMyoD and assume other cell fates or die. There is amajor
muscle deficit, with the presence of only those muscles derived
from the primary myotome that formed as a result of early activa-
tion of Myf5 through the epaxial enhancer. Pax3 transcription is
downregulated in fetal muscle when Pax7 becomes the domi-
nant factor in all myogenic progenitor cells. In the limb, Pax7 is
initially coexpressed with Pax3 and genetic tracing experiments
show that all later Pax7-positive cells in the fetal limb are derived
fromcells that had expressedPax3 (Hutcheson et al., 2009). Acti-
vation of fetal-specific muscle genes depends on the Nfix tran-
scription factor, where Nfix is a potential Pax7 target (Messina
et al., 2010). Postnatal and adult satellite cells are marked by
Pax7 expression, with continuing transcription of Pax3 in trunk
muscles such as the diaphragm and some limb muscles (see
Montarras et al., 2013). Prior to birth, Pax7 is not essential for
myogenesis, presumably because Pax3 can compensate. After
birth, on the other hand, Pax7 mutants lose their satellite cells
and Pax3 cannot compensate even in trunk muscles such as
the diaphragm, perhaps because the protein is present at too
low a level or because of divergent Pax3 and Pax7 functions by
this stage (Soleimani et al., 2012a). Pax7-negative satellite cells
can initiate differentiation, probably due to transcription of
Myf5 in an increasing number of these cells from the perinatal
period. Consistent with a role for Pax7 in the initiation of MyoD
but not Myf5 transcription in most satellite cells in culture, intro-
duction of dominant-negative Pax7 specifically abolishes MyoD
(Relaix et al., 2006) but notMyf5 expression or satellite cell differ-
entiation. The role of Pax7 in adult satellite cells has been contro-
versial. A first report on conditional Pax7 mutants indicated that
the satellite cell population was still present and that muscle
regeneration could take place, even in the absence of both
Pax7 and Pax3 (Lepper et al., 2009). Since then this view has
been modified and in a more extensive study muscle regenera-
tion was shown to be severely impaired when Pax7 ablation is
attained in most satellite cells, preventing repopulation of the
satellite cell pool (Gu¨nther et al., 2013; von Maltzahn et al.,
2013). In this adult situation the satellite cell pool is not main-
tained, not due to cell death but probably because of premature
differentiation at the expense of proliferation (Gu¨nther et al.,
2013). Pax3/Pax7 are normally downregulated prior to activation
ofMyogenin, cell cycle exit, and differentiation. Artificial mainte-
nance of their expression in myoblasts has been reported to
retard differentiation (Crist et al., 2012; Olguin and Olwin,228 Developmental Cell 28, February 10, 2014 ª2014 Elsevier Inc.2004). In this context, it has been proposed that Pax3 can pro-
mote satellite cell proliferation (Conboy and Rando, 2002). As
in the embryo, Pax intervention in the balance between self-
renewal and differentiation is probably critical.
Very little is known about Pax7 targets in satellite cells during
muscle regeneration. In addition to Pax7 activation of MyoD
through a site in the promoter (Hu et al., 2008), the 110 kb
element upstream of Myf5 has now been shown to be active in
satellite cells where it binds Pax7 (Soleimani et al., 2012a).
Pax3/7 has been shown to directly activate Id3, which encodes
a HLH inhibitor of myogenic factor activity, potentially prevent-
ing, together with Id2, the onset of myogenesis in quiescent
satellite cells (Kumar et al., 2009). New insight into potential
Pax7 targets in satellite cells comes from genome-wide ChIP-
seq and transcriptome analyses carried out on primary myo-
blasts derived from cultured satellite cells, in which a tagged
Pax7 protein was expressed (Soleimani et al., 2012a). This sug-
gests that Pax7 targets many genes implicated in satellite cell
function, including genes involved in cell growth, cell adhesion,
and signaling pathways, whereas it represses genes involved
in differentiation.
Transcriptional Mechanisms
In this analysis, tagged Pax3 was also expressed and shown to
bind to fewer sites than Pax7. Both factors bind through a paired
domain or paired and homeodomains, but Pax7 (not Pax3) also
binds with high affinity through the homeodomain only. This
therefore points to significant differences between the functions
of the factors. Pax3 does not rescue the postnatal phenotypes
of the Pax7 mutant in muscles where both proteins are present
in satellite cells. However, during myogenesis in the embryo,
Pax7, when it is coexpressed with Pax3, can compensate, as in
thePax3/Pax7progenitor cell population derived from the central
dermomyotome. Introduction of a Pax7 coding sequence into an
allele ofPax3 showed that Pax7 can replace Pax3 function during
myogenesis in the trunk and also partially in the limbs (see Buck-
ingham and Relaix, 2007). Functional differences between Pax3/
Pax7 in postnatal versus prenatal myogenesis may reflect post-
transcriptional modifications of the proteins and also association
with different cofactors. Pax3 activity requires phosphorylation
(Miller et al., 2008) and interferencewith this affectsPax3 function
in the hypaxial somite (Brunelli et al., 2007). During embryonic
myogenesis, Pax3 functions as a transcriptional activator (see
Buckingham and Relaix, 2007); however, like other Pax proteins,
it is a poor activator on its own, indicating the probable impor-
tance of coactivators. To date these have not been identified at
sites of myogenesis in vivo. Pax7 has been shown to interact
with the histone methyl transferase complex Wdr5-Ash2L-
MLL2, which directs activating H3K4 histone modifications
(McKinnell et al., 2008) in myoblasts from postnatal muscle.
Pax7 mutant satellite cells show reduced heterochromatin
condensation (Gu¨nther et al., 2013), pointing to a role in chro-
matin organization, also recently suggested for Pax3 (Bulut-Kar-
slioglu et al., 2012). Recent research begins to provide some
insight, but mechanistically much remains to be understood
about the function of Pax3 and Pax7 as transcription factors.
Six1 and Six4, with Eya1 and Eya2 Cofactors
Six homeodomain transcription factors, with Eya and Dach
cofactors (Kawakami et al., 2000), also play an important
AB
C
Figure 3. Gene Regulatory Networks that Govern Myogenesis
Shown in the trunk (A), the head (B), and in cells that migrate from the hypaxial
somite shown here for the forelimb (C).
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(Figure 3). Eya factors act as phosphatases and it is proposed
that this activity inhibits Dach corepressor function. Eya function
also involves recruitment of coactivators such as CBP to the Six
complex (Jemc and Rebay, 2007).
Functions of Six1/4 and Eya1/2 as Upstream Regulators
of Myogenesis in the Embryo
The first indication of an upstream function in myogenesis came
from experiments in the chick embryo where ectopic expression
of Six1 and Eya resulted in activation of Pax3 and myogenic
regulatory genes (Heanue et al., 1999). Since then, mutant anal-
ysis in the mouse has provided insight into the complex roles of
Six and Eya in activation of themyogenic program. In themouse,
Six1, Six4, Eya1, and Eya2 are expressed in the dermomyotomeand subsequently in Pax3-positive myogenic progenitors. Unlike
Pax3 and Pax7, these factors are also present in differentiated
skeletal muscle. In the dermomyotome, Eya1 and Eya2 are
mainly expressed in the epaxial and hypaxial domains, after
the initial onset of epaxial myogenesis. The critical role of Six/
Eya in myogenesis is revealed by the phenotypes of Six1/Six4
and Eya1/Eya2 double mutants (Grifone et al., 2005, 2007),
which are more severe than in the single Six1 mutant, with loss
of all muscles derived from the hypaxial dermomyotome,
including limb and many trunk muscles. Although Six/Eya is
not active in the central dermomyotome, the myogenic contribu-
tion fromPax3/Pax7 progenitors derived from this domain is also
compromised, as indicated by later fetal phenotypes, suggest-
ing an indirect effect due to the absence of hypaxial muscles.
Epaxial myogenesis leading to the formation of back muscles
takes place. This probably reflects its early onset, prior to a func-
tional effect of Six regulation. Furthermore, there is no evidence
of a requirement for Six sites in the EEE of Myf5. Myogenesis
arising from posterior somites is not affected in the mutant,
reflecting the absence of Six/Eya activity, as indicated by a
transgene reporter (Grifone et al., 2007). In these Eya or Six dou-
ble mutants, Six1/4 or Eya1/2 expression, respectively, is not
impaired, indicating that they are not interdependent.
There are two striking features of these double mutants. First,
Pax3 expression is lost in the hypaxial dermomyotome, which
would account for the absence of progenitor cell migration and
cell death. Surviving cells do not migrate but mislocate and
acquire other cell fates, reminiscent of the Lbx1 mutant (see
section on limbmuscle progenitors). Pax3 targets in the hypaxial
dermomyotome, such as Lbx1 or c-met, are not expressed,
possibly also reflecting a direct effect of Six1/4, since this pheno-
type is observed prior to the major loss of Pax3 and cell death.
Downregulation of Pax3 may be effected through a hypaxial
enhancer upstream of the promoter, which can direct transgene
expression to this domain in anterior somites (Brown et al., 2005)
and binds Six1 in vivo (Grifone et al., 2007).
The second striking feature of the double mutants is the
pronounced downregulation of myogenic regulatory genes
from the time when the Six/Eya complex would normally be
active. This is particularly pronounced forMrf4,which is no longer
expressed at sites of hypaxialmyogenesis in the trunk, and is also
seen forMyf5 andMyoD. Six/Eya directly regulates enhancer el-
ements of the Myf5 and MyoD genes. For Myf5 this has been
demonstrated for the 57.5 enhancer that controlsMyf5 activa-
tion in the limbs and mature hypaxial dermomyotome (Giordani
et al., 2007). Thus, Six and Pax are required together for correct
expression of Myf5 directed by the 57.5 enhancer. MyoD
expression is controlled by an embryonic enhancer (CE) at
20 kb and a second distal enhancer at 6 kb (DRR) (see Taps-
cott, 2005). Both of these regulatory elements contain sites that
bind Six1 and Six4 and interact with Six/Eya complexes in vivo.
Mutation of these sites results in almost complete abolition of
expression of a transgene controlled by the two enhancers and
the proximal promoter, demonstrating direct regulation of
MyoD by the Six/Eya complex (Relaix et al., 2013). This is
observed not only in the trunk and limbs, but also in head mus-
cles, where Six genes are expressed at sites of myogenesis.
However Six1/Six4 double mutants did not show any phenotype
in these muscles, probably due to compensation by Six2.Developmental Cell 28, February 10, 2014 ª2014 Elsevier Inc. 229
Developmental Cell
ReviewIn the genetic hierarchy that regulates the onset of myogenesis
(Figure 3), Six activation ofMyoD is an important facet.Six1/Six4/
Myf5(Mrf4) compound mutants do not activateMyoD and do not
form skeletal muscles in the trunk and limbs (Relaix et al., 2013).
This resembles the phenotype of Pax3/Myf5(Mrf4) mutants
(Tajbakhsh et al., 1997). It is perhaps surprising that in the
Pax3/Myf5(Mrf4) compound mutants, later activation of MyoD
by Six/Eya, or indeed by Pax7, does not take place in the
absence of Pax3. This points to the importance of the early
myotome as a scaffold and source of signaling molecules for
subsequent myogenesis, as well as the role of Pax3 in the
survival of thosemyogenic progenitors that do not express Pax7.
Six genes are also expressed in adult satellite cells, where Six1
plays a role in regulating the regenerative capacity of these cells
and their proliferation (Le Grand et al., 2012; Yajima et al., 2010),
properties that are also Pax7 dependent.
Regulation of Skeletal Muscle Differentiation by Six/Eya
The proximal regulatory region of Myogenin is also directly
controlled by Six factors (Spitz et al., 1998) and again the double
Six1/Six4 and Eya1/Eya2 mutant phenotypes indicate Six/Eya
regulation of this myogenic differentiation gene. Transcription
of Myogenin also depends on other elements (Cheng et al.,
1993; Yee and Rigby, 1993), which probably accounts for Six-
independent expression of Myogenin, seen at remaining sites
of muscle differentiation.
Six/Eya also controls downstream muscle genes, notably
those associated with a fast glycolytic muscle phenotype that
are downregulated in Six1/Six4 double mutants (Richard et al.,
2011). Sox6, involved in suppressing the slowmuscle phenotype
in the mouse embryo, is not expressed in the Six1/Six4 double
mutant. Six1 and Six4 bind to and transactivate regulatory
regions of fast muscle genes (Niro et al., 2010). Six1 and Eya1
are enriched in fast glycolytic fibers of adult muscle and their
forced expression in slow oxidative fibers will convert them to
a fast glycolytic phenotype. These effects on the activation of
downstream transcription factor and muscle genes distinguish
Six/Eya from Pax regulation of myogenesis. Pax7 may directly
repress genes required for differentiation (Soleimani et al.,
2012a), but the main role of Pax3 and Pax7 is in controlling
upstream events leading to myogenesis. Pax3 is active in the
somite prior to Six/Eya intervention and has more wide-reaching
effects at the onset of myogensis. However, Six/Eya play amajor
role in the onset of hypaxial myogensis, both directly through
activation of myogenic determination genes and also indirectly
through control of Pax3 (Figure 3A).
Pitx2
The three Pitx genes present in vertebrates encode a family of
paired-related homeodomain transcription factors. They were
first identified as regulators of pituitary development and play
an important role in the formation of multiple organs, in craniofa-
cial development, and in the late read-out of left/right signaling
(Gage et al., 1999).
Pitx Function during Myogenesis in the Trunk and Limbs
During myogenesis in the embryo, Pitx2 is expressed in
myogenic progenitor cells whereas Pitx3 is expressed in differ-
entiating muscle where it is replaced by Pitx2 in the Pitx3mutant
(L’Honore´ et al., 2007). In the absence of Pitx2 (L’honore´ et al.,
2010), the onset of myogenesis in the limb is affected and there230 Developmental Cell 28, February 10, 2014 ª2014 Elsevier Inc.are also minor myogenic defects in the somite. These are due to
downregulation of MyoD, which is compensated by Myf5. Pitx2
regulates the CE at20 kb that activatesMyoD in the limb. In the
somite, Pitx2 also directly controls MyoD transcription through
sites in the CE enhancer and a site adjacent to the promoter.
The DRR at 6 kb is also implicated, where Pitx2 may act in
conjunction with SRF which directly regulates the DRR. In
Myf5(Mrf4)/Pitx2 compound mutants, skeletal muscle does not
form. This phenotype is similar to that of the Myf5(Mrf4)/Pax3
compound mutant, suggesting that Pitx2 lies genetically down-
stream of Pax3 (Figure 3A). In gain-of-function screens for
Pax3 targets in myogenic progenitors in the embryo, Pitx2 was
upregulated, consistent with it being a Pax3 target (Lagha
et al., 2010). In the Pitx2 mutant, there are fewer proliferating
myogenic cells in the somite, potentially reflecting a role in medi-
ating proliferation (Kioussi et al., 2002).
Pitx2 and Other Factors that Control the Onset of
Myogenesis in Head Muscles
Pax3 is not expressed at sites of head muscle formation and it
is Pitx2 that plays a major role as an upstream regulator of
craniofacial myogenesis (Figure 3B; see Sambasivan et al.,
2011). Pax7 is expressed later, together with Pitx2, and marks
satellite cells, as in the trunk and limbs. Extraocular muscles
are absent in Pitx2 mutant embryos where extensive cell death
takes place in the premyogenic mesoderm. By a conditional
mesoderm deletion of Pitx2, activated after the critical period
of cell survival, downregulation of Myf5 and Mrf4, which control
the onset of myogenesis in these muscles, is observed and
MyoD is not expressed (Zacharias et al., 2011). Experiments in
cell cultures suggest that Pitx2 directly activates Myf5 as well
as MyoD through sites in the promoter region. At the onset of
extraocular muscle formation, Pitx2 therefore regulates both
progenitor cell survival and myogenic specification, assuming
the role of Pax3 at sites of myogenesis in the body. Comparison
of myogenic cells from extraocular and limb muscles indicates
that the former express higher levels of Pitx2, required for their
proliferation and differentiation, and that this high level is main-
tained in aging and in dystrophic muscles. This may be related
to the remarkable sparing of these muscles in muscular dystro-
phies (Hebert et al., 2013). Recent transcriptome profiling in
postnatal extraocular muscles of conditional Pitx2 mutants sug-
gests that Pitx2 may be important for maintaining the expression
of downstream muscle genes that characterize the extraocular
phenotype (Zhou et al., 2012).
The formation of masticatory muscles that derive from the first
branchial arch is also defective in Pitx2 mutants (see Sambasi-
van et al., 2011). Pitx2 is expressed in ectoderm as well as
mesoderm of the first arch, but a conditional deletion targeted
to the mesoderm demonstrates that the survival and growth of
myogenic progenitors are compromised and myogenic determi-
nation genes are not activated.
The T-box transcription factor Tbx1 is another regulator of
myogenic progenitors in the first branchial arch. In Tbx1mutants
the more posterior arches are lost, but the first arch is main-
tained. Masticatory muscles derived from the first arch are
hypoplastic. Again, conditional mutants directed to mesoderm
indicate that this is a direct effect rather than one that ismediated
by endodermal or ectodermal expression of Tbx1. Since Tbx1
directly activates Fgf8 and Fgf10, myogenic defects may be
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itor population, which depends on FGF signaling. However, in
Tbx1/Myf5 double mutants, all muscles derived from the first
branchial arch are absent, suggesting that these genes act
upstream of MyoD. It had been suggested that Tbx1 and Pitx2
may regulate each other, but in the Pitx2mutant, Tbx1 continues
to be expressed (Dong et al., 2006).
Tbx1 and Pitx2 are also present in cardiac progenitor cells,
marked by Islet1 expression. In this anterior region of the embryo,
the distinction between paraxial mesoderm that gives rise to
skeletal muscle and splanchnic mesoderm of the second heart
field that is the source of myocardial cells is blurred. Retrospec-
tive clonal analysis shows that a common progenitor gives rise to
branchial-arch-derived skeletal muscles and to the arterial pole
of the heart (Lescroart et al., 2010). In the mesodermal core of
the branchial arches, progenitors for both muscle cell types are
present, with myogenic progenitors that will activate myogenic
determination genes located more proximally. Genetic tracing
with an Islet1-Cre shows labeling of facial expression muscles
and a subset of masticatory muscles. Islet1 mutants die before
head muscle formation but overexpression of Islet1 represses
myogenic differentiation (see Tzahor and Evans, 2011).
Two bHLH transcription factors, Msc (MyoR) and Tcf21
(Capsulin), are expressed in myogenic progenitors in the arches,
prior to activation of themyogenic regulatory genes (see Samba-
sivan et al., 2011). InMsc/Tcf21 double mutants, major mastica-
tory muscles are lost and Myf5 is downregulated in myogenic
cells in both arches. Tbx1 is upregulated in the Msc mutant
when Myf5 and MyoD levels are reduced, suggesting that cells
remain in a progenitor state. Multiple Myf5 regulatory elements
direct transcription of this myogenic regulatory gene in the bran-
chial arches. TheMyf5 proximal arch element, which is important
for early expression, bindsMsc and Tcf21 in vivo and these bind-
ing sites are necessary for the correct expression of Myf5 in a
subset of cells. The DRR at 6 kb and the promoter region of
MyoD also bind Msc and Tcf21. The implication is that Msc
and Tcf21 function as transcriptional activators for Myf5 and
MyoD, controlling their levels of expression and thus regulating
myogenic determination in the arches (Moncaut et al., 2012).
These factors can also potentially interfere withmyogenic activa-
tion by MRFs and in a recent ChIP-seq study, Msc binding sites
in the genome have been shown to overlap with those for MyoD
(MacQuarrie et al., 2013). It is not clear how Msc and Tcf21 are
regulated in the arches, but Pitx2 and Tbx1 are potential candi-
dates.
The transcription factor Lhx2 has been identified as a com-
ponent in the hierarchy regulating myogenesis in the branchial
arches (Figure 3B). Lhx2 lies genetically downstream of Tbx1,
Pitx2, and Tcf21 and upstream ofMyf5. In vivo ChIP experiments
suggest that Lhx2may be directly regulated by Tbx1, Pitx2, and
Tcf21. Lhx2mutants have defects in branchial arch specification
of myogenic cells and head muscle patterning, whereas Tbx1/
Lhx2 double mutants lack branchial arch muscles (Harel et al.,
2012).
Lbx1, Msx1, Sim1, and Meox2 in Limb Muscle
Progenitors
Myogenic progenitor cells that migrate from the hypaxial somite
to form more distant muscles such as those in the limb are regu-lated by Pax3 but also by an additional gene hierarchy
(Figure 3C) implicated in migration and in the avoidance of pre-
mature myogenesis in migrating cells.
The Pax3 target c-met encodes a tyrosine kinase receptor
required for delamination of migratory cells. Interaction with its
ligand, HGF, present in the adjacent mesenchyme, is also impor-
tant for guiding cell migration (see Birchmeier and Brohmann,
2000). This regulation is essential for limb progenitors and also
for other migrating myogenic cells such as those that form the
diaphragm. The homeodomain factor Lbx1 controls the migra-
tion of myogenic progenitor cells through its activation of
CXCR4, which encodes the receptor for SDFI (Vasyutina et al.,
2005). In Lbx1 mutants, muscles in the hindlimbs and dorsal
forelimbs are absent with mislocation of Pax3-positive cells
adjacent to the somites (Scha¨fer and Braun, 1999). Lbx1 is a
potential Pax3 target (Lagha et al., 2010); however, Lbx1 is not
expressed at all axial levels, but in the hypaxial domain of
somites that give rise to migrating cells, as at limb level. Hox
factors intervene in the activation of Lbx1 (Alvares et al., 2003),
thus providing an indication of how the Hox code influences
myogenesis on the anterior/posterior axis. Meox2, together
with Meox1, is expressed in somites all along the axis. Meox2
continues to be present in migrating myogenic progenitors. It
does not appear to affect migration, but in the Meox2 mutant
certain limb muscles are lost, notably in the forelimb. Once
progenitor cells reach the limb, Pax3 expression is downregu-
lated and there is a delay in Myf5 activation (Mankoo et al.,
1999), in keeping with the role of Meox homeodomain proteins
as transcriptional activators.
An important question for myogenesis is why progenitor cells
expressing factors such as Pax3 or Six/Eya do not immediately
activate downstream myogenic factor genes and differentiate.
Under some conditions this is probably due to the modulating
effect of signaling pathways such as Notch or FGF. It may also
reflect the presence of corepressors such as Dach, present in
the Six-positive cells that migrate to the limb (Heanue et al.,
1999). However, in the context of the limb, there is also evidence
for the action of transcriptional repressors such as the homeodo-
main protein Msx1 or the bHLH-PAS-domain factor Sim2.Msx1
is expressed in the hypaxial dermomyotome and in migrating
Pax3-positive cells, at forelimb level (Houzelstein et al., 1999).
Msx1 in this context is directly regulated by Tcf4 (Miller et al.,
2007), suggesting a role in limb muscle patterning that is under
the control of canonical Wnt signaling (Hutcheson et al., 2009).
Msx1 is downregulated prior to activation of Myf5. Forced
expression of Msx1 antagonizes differentiation in muscle cell
lines (Song et al., 1992) and prevents myogenic conversion of
fibroblasts by MyoD, with recruitment of the linker histone H1B
that represses MyoD transcription (see Tapscott, 2005). More
recently Msx1 has been shown to recruit the repressive Poly-
comb complex to the 20 kb enhancer of MyoD and to the
Myf5 57.5 kb regulatory region that controls the onset of
expression in the limbs (Wang et al., 2011). This is accompanied
by a redistribution of H3K27me3 repressivemarks due to recruit-
ment of G9a methyltransferase (Wang and Abate-Shen, 2012).
The developmental significance of these observations is sug-
gested by Myf5 upregulation in the forelimbs of Msx1 mutant
embryos (Wang et al., 2011). Sim2 is expressed in muscle
progenitors in the limb, prior to their entry into the myogenicDevelopmental Cell 28, February 10, 2014 ª2014 Elsevier Inc. 231
Figure 4. MicroRNARegulatory Networks in
Satellite Cells as They Progress toward
Differentiation, when Cultured or during
Regeneration of Adult Muscle after Injury
Abbreviation: miR, microRNA.
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repressesMyoD expression, thereby also preventing premature
activation of myogenesis in Pax3-positive progenitors (Havis
et al., 2012). Its expression principally in ventral muscle masses,
indirectly under the repressive action of the dorsalizing factor
Lmx1b, also provides insight into muscle patterning.
MicroRNAs
Transcriptional regulation of the onset of skeletal muscle for-
mation is modified by posttranscriptional mechanisms that
affect the presence and function of the transcription factors
concerned. MicroRNAs (miRNAs), which impact mRNA stability
and translation through interaction with specific sites in the 30
UTR, have emerged as important components of the myogenic
regulatory network (Figure 4; see Gagan et al., 2012; Goljanek-
Whysall et al., 2012). Pax3 and Pax7 mRNAs are both targeted
by miR206 and in addition they are targeted by miR27 and by
miR486 and miR1, respectively. These miRNAs are present in
myogenic cells that express MyoD and Myf5 and play a role in
the downregulation of the Pax factors when the cells differen-
tiate, as well as affecting their survival and/or proliferation. Their
role in modulating the onset of differentiation is illustrated by a
recent report on miR206 that promotes muscle regeneration
(Liu et al., 2012). The miR206 gene is directly activated by
MyoD and Pitx2 has been reported to regulate the expression
of miR27 in cultured muscle cells. Susceptibility to miRNA
regulation depends on the 30 UTR sequence, which may vary
in different splice forms of the mRNA. In the case of Pax3, in
different populations of myogenic progenitors, alternative polya-
denylation results in transcripts that have longer or shorter 30
UTRs, where only the longer form has miR206 and miR27 sites
(Boutet et al., 2012), thus affecting Pax3 regulation. The mRNA
for Msc is targeted by miR378, which is under MyoD control.
The mRNA for Myf5 is targeted by miR31, preventing pre-
cocious activation of myogenesis in the epaxial dermomyotome
or inappropriate and potentially dangerous myogenesis in re-
gions of the central nervous system where Myf5 is transcribed
in the mouse embryo. It also prevents accumulation of Myf5
protein and consequent activation of myogenesis in quiescent
satellite cells, many of which transcribe Myf5 and in which the
mRNA is sequestered in RNP particles with miR31 (Crist et al.,
2012). Experiments, principally on muscle satellite cells, have232 Developmental Cell 28, February 10, 2014 ª2014 Elsevier Inc.revealed miRNA control of proliferation
via mRNAs coding for regulators of the
cell cycle, thus promoting satellite cell
quiescence or cell cycle withdrawal prior
to differentiation. miRNAs also fine-tune
signaling pathways that play a role in
myogenesis, such as the IGF pathway,
or regulate miRNA genes as shown for
TGFb that represses miR1/206. In addi-
tion to the MRFs, Mef2 factors are alsokey regulators of muscle genes at the onset of differentiation.
Mef2c, like MyoD, activatesmiR1/206/133 gene clusters. Again,
feedback circuits operate such that miR1 controls the level of
HDAC4 that represses Mef2C, whereas miR133 targets the
mRNA of MAML1, which is a coactivator of Mef2. A new level
of complexity emerges with the demonstration that the preRNA
for miR133 also encodes a competing endogenous (ce) RNA,
linc-MD1, which binds to and sequesters miR133 and also
miR135, which targets themRNA forMef2c (Cesana et al., 2011).
MicroRNAs also regulate the muscle phenotype. miRNAs
encoded by introns of slow myosin genes modulate the expres-
sion of factors that control slow versus fast fiber type specifica-
tion. Recently it has been shown that miRNAs can play an
upstream role in cell fate determination. Adult satellite cells nor-
mally enter myogenesis and form muscle fibers. However, they
transcribe Prdm16 that encodes a transcriptional regulator of
brown fat, derived from Pax3-expressing cells in the somite.
miR133 targets the 30 UTR of Prdm16mRNA and prevents accu-
mulation of Prdm16. In the absence of miR133 activity, satellite
cells give rise to brown adipocytes and it is proposed that down-
regulation of miR133 on cold exposure permits satellite cell con-
version to thermogenic brown fat cells (Yin et al., 2013).
Thus, posttranscriptional control of myogenesis by miRs is an
important facet of the regulatory network (Figure 4). We have
discussed examples that affect upstream factors, but the
miRNAs mentioned have multiple targets and many other
miRNAs are present in muscle cells, so that their modulating
influence is likely to be highly complex. In addition to other
classic mechanisms that impact mRNA or protein levels and
function, other classes of noncoding RNAs are just beginning
to emerge as additional layers that confer transcriptional or post-
transcriptional regulation.
Mechanisms Underlying MRF Function
Once the cascade of MRFs has been activated, these bHLH
transcription factors act as obligate heterodimers with the ubiq-
uitously expressed E proteins to activate the terminal differenti-
ation program by regulating the transcription of many genes
including those encoding the contractile proteins and muscle-
specific enzymes, as well as a number of miRNAs (Figure 4). It
has been known for many years that MRFs do this, at least in
part, by binding to E-boxes in the promoters and enhancers of
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polymerase II (PolII), and that they often act in concert with other
transcription factors, for example Mef2. Most of this knowledge
is derived from experiments on single genes. The advent of
genome-wide technologies has allowed these issues to be
readdressed and led to a number of important new mechanistic
insights.
Much of this work has used as a model the in vitro differentia-
tion of the C2 muscle cell line and analyzed the transcriptome,
protein-DNA interactions, and epigenetic modifications in prolif-
erating myoblasts and in nondividing myotubes derived from
them. C2 cells are generally thought to be related to satellite cells
that are derived from muscle progenitors in the embryo: the
generalizability of the conclusions that we will discuss has not
been extensively tested. A second widely used approach has
been to introduce one of the MRFs, almost always MyoD, into
a naive cell, usually mouse embryonic fibroblasts (MEFs), and
then to study what happens as these cells enter the myogenic
program and differentiate into myotubes. Microarray experi-
ments identified the genes that are regulated, in multiple waves,
during this transition and indicated that MyoD acts at all stages
of the differentiation process via a feed-forward loop (see Taps-
cott, 2005). The assumption was, of course, that MyoD was
bound to the control elements of the genes being regulated
and ChIP-seq technologies have now been used to test the
assumption, with some surprising results.
How Many MyoD Binding Sites Are There?
Cao et al. (2010) found that the protein bound to the control
elements of genes regulated during differentiation but also to a
very large number of sites not obviously associated with such
regulated genes. The number of sites (23k in C2 myoblasts,
26k in myotubes) is much higher than expected and most of
the sites are the same in the two cell types. The function of the
additional binding sites is not clear. Most of them are inactive
in a transfection assay for enhancer function, so they could
reflect an unknown function of MyoD or simply the fact that the
protein will bind to all E-boxes with some affinity. Mousavi
et al. (2013) have performed a similar analysis and also detected
an unexpectedly high number of sites (18k in myoblasts, 40k in
myotubes). Furthermore, they found 35k Myogenin (MyoG) sites
in myotubes, the majority of which overlap with MyoD sites.
Soleimani et al. (2012b) did the experiment differently, using
retroviral transduction to introduce a TAP-tagged MyoD into
myoblasts derived from cultured satellite cells and then the tag
to recover the protein and its bound DNA. They found a much
smaller number of sites (1.4k in myoblasts, 9.3k in myotubes)
and observed a significant difference between the cell types.
The exogenous protein is expressed at a higher level than the
endogenous one but that would be expected to lead to more
occupied sites, not less, and Yao et al. (2013) have shown that
4-fold overexpression of MyoD does not lead to a significant
increase in the number of bound sites. Apart from analysis of
endogenous protein versus tagged exogenous MyoD on a
wild-type background, the reasons for this interestingly different
result may lie in the data handling and analysis pipelines; no
doubt future work will clarify the situation.
Blum et al. (2012) have taken a different approach, identi-
fying enhancers in C2 myoblasts and myotubes on the basis
of histone marks and then asking whether PolII, transcriptionfactors, and coactivators are bound to them. The identified en-
hancers that are close to genes are linked to those expressed
in the relevant cell type but rather few of these condition-
specific ‘‘enhancers’’ are associated with transcripts (eRNAs).
Perhaps the marks analyzed are found on elements with other
functions? Comparisons with the data of Cao et al. (2010)
show that MyoD binding to enhancers correlates with the bind-
ing of PolII and p300; in MyoD/ cells these proteins are not
present and there is a significant decrease in transcription
across the enhancers. Reintroduction of MyoD in null
myoblasts causes a restoration of PolII binding and H3K4
monomethylation but not of H3K27 acetylation, whereas in
myotubes acetylation is restored as well. Such re-expression
experiments are an important way to examine cause and effect
relationships.
How Does MyoD Find the Right Sites?
What is clear is that these and related data have illuminated a
number ofmechanistic questions that have preoccupied the field
for many years. Just as MyoD regulates muscle-specific genes,
the closely related transcription factor NeuroD drives a neuronal
program. How is it that transcriptional activation by two very
similar proteins can lead to such different outcomes? Fong
et al. (2012) introduced NeuroD into P19 cells, a pluripotential
mouse embryonal carcinoma cell line, and thus converted
them into neurons, and MyoD into MEFs. NeuroD can not
convert MEFs into neurons and MyoD can not convert P19s
into muscle. The data again show an unexpectedly high number
of binding sites, for both factors, but they reveal a very interesting
specificity. Both proteins bind to the CAGCTG E-box but they
each also bind to a particular E-box (CAGATG for NeuroD and
CAGGTG for MyoD), and this binding is translated into differ-
ential function. Binding to the specific E-box sequences leads
to activation of adjacent genes whereas binding to the common
sequence correlates with regional epigenetic modification. The
binding of both MyoD and NeuroD is constrained by chromatin
accessibility and thus which sites are open is determined epige-
netically in a lineage-specific fashion; sequence specificity then
dictates which factor bindswhere and thus which genes are sub-
sequently activated.
A Novel Mechanism of Transactivation
It has become apparent in recent years that a very high propor-
tion of the genome is transcribed into a variety of classes of RNA
that do not encode proteins. Of particular interest in the present
context are eRNAs, which may or may not be polyadenylated
and are transcribed from active enhancers. These eRNAs may
be functional, or they may simply be a by-product of the fact
that PolII is loaded onto active enhancers. Mousavi et al.
(2013) used RNA-seq to show that the majority of the MyoD/
MyoG peaks that also bind PolII and are marked by H3K4me1
and H3K27ac are transcribed in both senses inmyotubes. siRNA
knockdown of MyoD but not of MyoG reduced the level of these
eRNAs. Among the enhancers that are transcribed in C2 myo-
tubes, and in FACS-sorted satellite cells, are the two well-char-
acterizedMyoD elements, the CE and the DRR. siRNAs targeted
to the CE eRNAs but not those to the DRR eRNAs caused a
significant reduction in MyoD mRNA and protein indicating that
transcription from the CE is required for efficient MyoD expres-
sion, although one cannot tell whether the eRNA acts in cis or
in trans. This is an interesting demonstration that at least someDevelopmental Cell 28, February 10, 2014 ª2014 Elsevier Inc. 233
Figure 5. Schematics of Different Molecular Models for the Transcriptional Regulation of Muscle Genes in Myoblasts and Myotubes
These are based on results discussed in the review, are not comprehensive, and are not mutually exclusive. Indeed, all may operate simultaneously. Circles
represent proteins binding to DNA regulatory elements; open circles are activators and hatched circles are repressors. Abbreviation: P, phosphorylated.
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gous experiments targeting the DRR eRNAs. Knocking them
down prevents the activation of the MyoD target genes MyoG
and myosin heavy chain. Conversely, when retroviral transduc-
tion was used to overexpress some but not all of the DRR eRNAs
in C2 myoblasts, MyoG expression, and thus the rest of the
myogenic program, was activated without any effect on MyoD
transcript levels. Both types of eRNA affect chromatin accessi-
bility at their target loci. The data thus say that eRNA from one
of theMyoD enhancers acts in trans to activate the transcription
of a gene well known to be a direct target of the MyoD protein.
The eRNA will appear in the cell before MyoD protein, which
will allow it to modulate the accessibility of the MyoG promoter
so that it is receptive to the transcription factor. This is a novel
mechanism (Figure 5) and it will be most interesting to know
whether it operates in all muscle progenitors. However, it should
be noted that it can not be essential for the basic function of234 Developmental Cell 28, February 10, 2014 ª2014 Elsevier Inc.MyoD because ectopic expression from heterologous regulatory
elements will trigger the myogenic program and the DRR is
dispensible for MyoD expression at embryonic and neonatal
stages.
Regulation of the Onset of Differentiation
Proliferating myoblasts expressMyoD, so why do they not differ-
entiate until the appropriate culture medium is provided? One
explanation had been the presence of Id or one of the other inhib-
itory proteins that prevent MyoD binding to DNA, although this is
not readily compatible with the fact thatMyoD is transcriptionally
active in myoblasts, nor with the data that say that MyoD is
bound to the same sites in myoblasts and myotubes. Never-
theless, somehow the transcription factor is prevented from
activating those targets destined to be expressed in myotubes
and Soleimani et al. (2012b) have provided a rather satisfying
answer to this conundrum. As well as the bHLH proteins,
E-boxes are also bound by a number of zinc-finger proteins
Developmental Cell
Reviewincluding the transcriptional repressor Snail, which recruits the
histone deacetylases HDAC1 and HDAC2. Snail binds to
E-boxes with a G/C-rich central dinucleotide, which are asso-
ciated with genes expressed in myotubes but not to E-boxes
with an A/T-rich central dinucleotide, which are associated
with genes expressed in myoblasts. When differentiation is
triggered, Snail must be removed in order to allowMyoD access.
Among the genes regulated by MyoD are those encoding
miR30a, which targets Snail1 mRNA, and miR206, which targets
Snail2 mRNA. Overexpression of Snail blocks differentiation
whereas siRNA knockdown of this repressor induces precocious
differentiation. They therefore propose that when cells receive a
differentiation signal, the MRFs activate the miRNAs which
prevent further translation of Snail mRNAs. As the unstable Snail
proteins turn over, MyoD gains access to the E-boxes of the
myotube genes and activates the terminal differentiation pro-
gram. Another zinc-finger protein, ZEB1, also binds to E-boxes
with a G/C-rich central dinucleotide and represses transcription,
in this case through association with the corepressor CtBP. ChIP
experiments show that ZEB1 is bound to the promoters of
selected terminal differentiation genes in myoblasts but not in
myotubes and again knockdown of ZEB1 induces precocious
differentiation (Siles et al., 2013). The relationship between Snail
and ZEB1 function (Figure 5) is not clear from these data but
should be revealed by genome-wide experiments that analyze
both proteins.
Cooperation between MyoD and Other Transcription
Factors
It was clear from experiments with single genes that the MRFs
do not act in isolation but that they act in concert with other
transcription factors, the best-characterized example being the
proteins of the Mef2 family. The data from the ChIP-seq experi-
ments provide a genome-wide view of such cooperative inter-
actions, derived by examining the sequences around the sites
of MyoD binding and asking, by a variety of methods, what other
transcription factors could bind there. As expected, there are
frequent sites for proteins like Mef2 and RUNX, which have
been previously studied in the context of myogenesis, but also
sites for proteins such as PPAR-g and c-Myb, which have not at-
tracted much attention from the field. MacQuarrie et al. (2013)
have shown that several of the potential cooperating factors,
e.g., Mef2c and RUNX1, are expressed at lower than expected
levels in rhabdomyosarcoma tumor cells and that forcing their
expression induces the cells to enter the terminal differentiation
program. This observation provides strong biological support for
the notion that they do act cooperatively, as originally proposed,
on the basis of biochemical and reporter gene experiments, for
the case of MyoD and Mef2 by Molkentin et al. (1995).
Alternative Splicing of Mef2
Genome-wide approaches can also provide a great deal of
information about posttranscriptional regulation. Trapnell et al.
(2010) performed a large-scale RNA-seq time course analysis
of C2 differentiation that revealed that, in addition to the ubiqui-
tously expressed isoform ofMef2D (Mef2Da1), there is amuscle-
specific isoform (Mef2Da2) that appears relatively late in the
differentiation process as the result of alternative splicing. Se-
bastian et al. (2013) have explored the biological significance
of this observation and shown that overexpression of the mus-
cle-specific isoform accelerates differentiation and can inducethe expression of late genes in proliferating myoblasts. More
strikingly, in an in vivo model, the ubiquitous isoform impairs
regeneration whereas the muscle-specific one improves it. The
two proteins bind to largely overlapping genomic sites but there
are major differences in their interactomes. The ubiquitous
Mef2Da1 binds to corepressors, HDACs 4 and 9, whereas the
muscle-specific Mef2Da2 binds to the Ash2L coactivator com-
plex (Figure 5). The choice of binding partner is controlled by
protein kinase A phosphorylation; mutations that prevent this
modification of the ubiquitous isoform transform it into an acti-
vator. Regulated alternative splicing can thus have amajor effect
on the biological activity of one of the best-characterized tran-
scription factors involved in myogenesis.
MyoD and Chromatin Structure
It is clear from the work comparing MyoD and NeuroD that there
must be lineage-specific epigenetic marks that restrict transcrip-
tion factor access to chromatin. How these marks are set during
early embryogenesis is a major question for the future. The
activating transcription factor may be loaded in a way that is
insensitive to repressive marks or it may itself be able to induce
chromatin remodeling. In the first case the MRFmight be loaded
though interactions with a pioneer factor that can bind effectively
to adjacent target gene regulatory elements that do not carry
repressive marks or, more probably, in a fashion that is insensi-
tive to them. Pbx has been shown to interact with a noncanonical
homeodomain site upstream of MyoG in both muscle and non-
muscle cells and to facilitate the binding of MyoD to an E-box
close to the transcription start site (see Tapscott, 2005). It is clear
that the remodeling of chromatin structure is an important part of
the process by which the MRFs activate the terminal differentia-
tion program. MyoD binds directly to the BAF60c subunit of the
SWI/SNF chromatin remodeling complex and both proteins are
found at the promoters of untranscribed MyoD target genes in
myoblasts. When differentiation is signaled, BAF60c is phos-
phorylated by p38, which allows them to be incorporated into
the Brg1-based SWI/SNF complex with consequent chromatin
remodeling and transcription (Figure 5; Forcales et al., 2012).
Another possible mechanism for facilitating expression is the
removal of repressive epigenetic marks. The histone chaperone
Spt6 acts to remove nucleosomes in front of the elongating polII
complex and to reassemble them once the polymerase has
passed. It has recently been shown that Spt6 has another activity
that recruits the histone demethylase KDM6A (UTX), which
removes repressive H3K27me3 deposited by the Polycomb
Repressive Complex 2. This activity is required for the activation
of the terminal differentiation program in C2 cells (Wang et al.,
2013), and zebrafish mutant for Spt6 have muscle defects (Kok
et al., 2007). It is, of course, the case that these mechanisms
are not mutually exclusive.
Role of the Core Transcription Machinery
Relatively little attention has been paid to the role of the core
transcription machinery in the regulation of muscle-specific
gene expression, but this an area that warrants further attention.
The general transcription factor TFIID is comprised of TBP (the
TATA-box binding protein) and a number of TAFs. Deato and
Tjian (2007) have reported that TFIID is degraded during the
differentiation of C2 cells and replaced by a simpler complex
of TRF3 (a TBP-related factor) and TAF3. This new complex is
required for MyoD to activate the MyoG promoter through aDevelopmental Cell 28, February 10, 2014 ª2014 Elsevier Inc. 235
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et al., 2008) and knockdown of either component thus blocks
differentiation.
Conclusion
The genome-wide approaches have, for obvious logistical rea-
sons, used cultured cells. However, as we have discussed, there
are a number of distinct genetic programs which, in the embryo,
lead to the skeletal muscle phenotype. It will be of great interest
to ask detailed mechanistic questions about the activation of
differentiation in each of the progenitor populations, but this
will require ways of efficiently sorting the cells of interest and
improvements in the sensitivity of the assays. Such data would
allow us to link our understanding of the upstream regulatory
networks in the embryo (Figure 3) with our knowledge of the
biochemical mechanisms that lead to a skeletal muscle cell to
provide a satisfying, integrated understanding of the molecular
basis of myogenic determination and differentiation.
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